MK-677 (Ibutamoren) Endurance Athletes Protocol

What Is MK-677 and Why Do Endurance Athletes Use It?

MK-677 is a selective, non-peptide agonist of the ghrelin receptor (GHSR-1a) that stimulates the pituitary to release growth hormone in a pulsatile pattern that closely mirrors physiological secretion. Unlike exogenous recombinant HGH injections, MK-677 preserves the feedback axis and does not fully suppress endogenous GH production. Endurance athletes in running, cycling, and triathlon are drawn to it for three specific reasons: overnight connective-tissue repair, improved slow-wave sleep architecture, and lean-mass preservation during high training loads.

The GH-IGF-1 Axis and Why It Matters for Runners and Cyclists

Growth hormone drives hepatic IGF-1 synthesis, and IGF-1 is the downstream effector responsible for muscle protein synthesis and tendon collagen turnover. A 1998 phase II RCT by Chapman et al. (N=32, 2-week crossover) published in the Journal of Clinical Endocrinology and Metabolism demonstrated that a single 25 mg oral dose of MK-677 raised 24-hour mean serum GH from 1.4 to 6.1 ng/mL and IGF-1 by approximately 40% from baseline (Chapman et al., 1996, JCEM). For an endurance athlete accumulating 10 to 20 hours of weekly training, that sustained anabolic signal during sleep supports the collagen synthesis needed to protect tendons and fascia under repetitive load.

How MK-677 Differs from SARM Compounds

A common misconception groups MK-677 with selective androgen receptor modulators. MK-677 has no androgen receptor affinity. It works entirely through the GH secretagogue receptor. This distinction matters for athletes worried about androgenic side effects such as hair loss, prostate stimulation, or suppression of the hypothalamic-pituitary-gonadal axis. The FDA's current classification notes MK-677 is investigational and not approved for human use, but it is mechanistically separate from SARMs.

Clinical Evidence Supporting MK-677 Use in Athletic Populations

The evidence base is stronger than for most investigational compounds, with completed phase II and phase III trials. No large RCT has enrolled competitive endurance athletes specifically, so direct extrapolation requires caution.

Phase II and III RCT Data

The landmark 24-month study by Nass et al. (2008) enrolled 65 healthy older adults and showed that 25 mg of MK-677 daily increased IGF-1 by 40% at 12 months and maintained that elevation through month 24 without tachyphylaxis Nass et al., 2008, Ann Intern Med. Body-fat mass decreased significantly. Lean mass increased by a mean of 1.7 kg over the study period. Fasting glucose rose by a mean of 0.3 mmol/L, a clinically small but statistically significant finding that monitoring protocols must address.

A second key trial by Murphy et al. (1998, N=24) found that two years of MK-677 25 mg in older adults increased GH pulse amplitude without altering pulse frequency, and the pulsatile pattern remained physiological (Murphy et al., 1998, JCEM). Maintaining physiological GH pulsatility is one reason practitioners prefer MK-677 over continuous subcutaneous GHRH infusion.

Sleep Architecture Data

A randomized crossover trial by Copinschi et al. (1997, N=8 healthy young men) showed that 25 mg of MK-677 given at bedtime increased stage IV (slow-wave) sleep by 50% and REM sleep by 20% compared to placebo over 7 nights (Copinschi et al., 1997, Sleep). Slow-wave sleep is the window of peak endogenous GH release and the period when muscle and tendon repair is greatest. For triathletes and ultrarunners who already compromise sleep through early-morning sessions, this is a meaningful mechanism.

Bone Density and Connective Tissue

A 12-month RCT by Svensson et al. (1998, N=24) showed that MK-677 25 mg significantly increased bone formation markers (osteocalcin, bone-specific alkaline phosphatase) compared to placebo in healthy adults (Svensson et al., 1998, JCEM). Stress fracture risk is a documented concern in endurance athletes with high weekly mileage, and enhanced bone turnover toward formation rather than resorption is a plausible protective mechanism, though no fracture-endpoint trial in athletes exists yet.

The HealthRX Endurance Athlete Protocol for MK-677

The following protocol is derived from published RCT doses, observed IGF-1 response curves, and practitioner experience with recreational and competitive endurance athletes at HealthRX. It is not a substitute for individualized physician oversight.

Phase 1: Ramp-Up (Weeks 1 to 4)

Start at 12.5 mg orally, 30 to 60 minutes before sleep. Taking the dose at bedtime captures the natural nocturnal GH surge and reduces daytime hunger amplification. At 12.5 mg, most users see moderate IGF-1 increases (roughly 20 to 40% above baseline) with fewer water-retention complaints than at 25 mg. Run a baseline lab panel before the first dose.

Baseline labs required:

• Fasting serum IGF-1 (ng/mL)
• Fasting glucose and HbA1c
• Comprehensive metabolic panel
• Fasting lipid panel
• Prolactin (optional but useful as a GH-axis marker)
• Cortisol (AM, fasted)

Phase 2: Full Dose (Weeks 5 to 16)

If fasting glucose at week 4 remains below 100 mg/dL and the athlete tolerates the ramp dose, increase to 25 mg nightly. The Nass et al. 24-month trial used 25 mg throughout and found no additional glucose disruption when subjects maintained activity levels, suggesting the metabolic risk is lower in conditioned athletes than in the sedentary older adults studied.

Repeat labs at week 6:

• Fasting IGF-1 (target: upper-normal range for age and sex, typically 200 to 350 ng/mL for adults aged 25 to 45)
• Fasting glucose
• HbA1c (if baseline was 5.5% or above)

If IGF-1 exceeds 400 ng/mL, reduce to 12.5 mg and recheck in four weeks. Supraphysiological IGF-1 is associated with increased colon polyp risk in long-term epidemiological data Renehan et al., 2004, Lancet.

Phase 3: Maintenance or Cycling Decision (Weeks 17 to 24)

The Nass et al. 24-month data show no loss of efficacy through continuous use. Athletes can choose between:

1. Continuous use at 25 mg nightly for up to 24 months with quarterly IGF-1 and glucose monitoring.
2. On/off cycling of 16 weeks on, 4 weeks off, preferred by athletes who want a defined washout window around competition blocks or who experience appetite side effects during heavy training phases.

During the off phase, IGF-1 returns to baseline within approximately two to four weeks based on the half-life kinetics reported by Patchett et al. (Patchett et al., 1995, PNAS).

Timing Relative to Training

• Take MK-677 at least 2 hours after the final meal of the day. Co-ingestion with carbohydrates blunts the GH pulse through insulin-mediated somatostatin release.
• Do not take MK-677 pre-workout. The acute hunger amplification impairs high-intensity interval sessions and long runs.
• On double-training days (morning threshold run plus afternoon strength), take MK-677 after the evening session.

Side Effects Specific to Endurance Athletes

Water Retention and Body Weight Interpretation

MK-677 causes dose-dependent water retention through aldosterone-like renal sodium retention. Most athletes report 1 to 3 kg of acute scale weight gain in the first two to four weeks. This is not fat. Cyclists and runners monitoring power-to-weight or pace-to-weight ratios should not reduce calories in response. The fluid shifts stabilize by week 6 in the Nass et al. Data.

Appetite Amplification During High-Volume Weeks

The ghrelin-receptor agonism drives acute hunger increases that can be difficult during peak training blocks with 15 to 20 hours of weekly volume. Strategies that practitioners at HealthRX recommend: take MK-677 immediately before bed rather than one hour before, ensure adequate protein at the evening meal (at least 40 g), and accept modest caloric surplus during 12.5 mg ramp weeks rather than fighting hunger signals aggressively.

Fasting Hyperglycemia

The Nass et al. Trial reported a statistically significant increase in fasting glucose (P<0.05) of approximately 5.4 mg/dL at 12 months. For metabolically healthy endurance athletes with habitual high carbohydrate turnover, this rarely becomes clinically meaningful. Athletes with pre-diabetes (fasting glucose 100 to 125 mg/dL or HbA1c 5.7 to 6.4%) should use MK-677 only under close physician supervision with quarterly metabolic panels. The American Diabetes Association Standards of Care 2024 defines pre-diabetes thresholds and monitoring frequency that should guide decisions in this subgroup.

Carpal Tunnel-Type Paresthesias

Transient tingling in the hands, particularly on waking, occurs in a minority of users and is consistent with the mild fluid retention and GH-axis effects seen with exogenous GH therapy. It typically resolves spontaneously within four to six weeks or with dose reduction to 12.5 mg. Persistent or worsening symptoms warrant discontinuation and neurological evaluation.

Stacking MK-677 with Other Recovery Compounds

MK-677 Plus BPC-157 for Tendon Repair

Endurance athletes with chronic tendinopathies (Achilles, patellar, plantar fascia) sometimes combine MK-677 with BPC-157. BPC-157 is a synthetic pentadecapeptide with demonstrated tendon-healing effects in animal models (Krivic et al., 2006, J Orthop Res). The mechanistic rationale for combining them is additive: MK-677 elevates systemic IGF-1 to support collagen synthesis broadly, while BPC-157 may act locally via growth hormone receptor upregulation at the injury site. No human RCT exists for this combination. Evidence level: animal + mechanistic only.

MK-677 Plus Creatine Monohydrate

Creatine monohydrate (3 to 5 g daily) is one of the few supplements with consistent evidence for endurance recovery support, including reduced muscle damage markers. A Cochrane review of creatine supplementation (Rawson and Volek, referenced in Cochrane systematic reviews on creatine) supports its safety and tolerability. Combining creatine with MK-677 does not appear to cause pharmacological interaction. Both compounds increase intracellular water content and scale weight, so athletes should expect additive fluid retention of 1 to 2 additional kg in the first four weeks.

What Not to Stack

Avoid combining MK-677 with exogenous recombinant HGH. The result is double stimulation of GH/IGF-1 beyond the physiological range, with meaningfully increased risk of supraphysiological IGF-1 (above 400 ng/mL), acromegalic soft-tissue changes, and glucose dysregulation. The Endocrine Society Clinical Practice Guideline on adult GH deficiency (2011) specifies IGF-1 targets at the upper third of the age-adjusted normal range as the ceiling for replacement therapy, a ceiling that applies equally here.

Monitoring Protocol and Decision Tree

Lab Schedule

| Timepoint | Labs Required | |-----------|---------------| | Baseline (before dose 1) | IGF-1, fasting glucose, HbA1c, CMP, lipid panel | | Week 6 | IGF-1, fasting glucose | | Week 12 | IGF-1, fasting glucose, HbA1c | | Week 24 | Full panel (repeat baseline) | | Every 6 months (continuous use) | IGF-1, fasting glucose, HbA1c |

Dose Adjustment Rules

• IGF-1 below 150 ng/mL at week 6: increase to 25 mg if still at 12.5 mg ramp dose.
• IGF-1 above 400 ng/mL at any point: reduce dose by 50% and recheck in four weeks.
• Fasting glucose above 110 mg/dL on two consecutive measurements: reduce to 12.5 mg and add HbA1c monitoring every 8 weeks.
• Fasting glucose above 126 mg/dL: discontinue and refer for diabetes evaluation per ADA Standards 2024.

Regulatory and Anti-Doping Considerations

MK-677 is not approved by the FDA for any indication. The completed investigational new drug studies focused on GH deficiency and muscle wasting in older adults, not athletic performance. WADA lists it as prohibited under the S2 category (Peptide Hormones, Growth Factors, Related Substances and Mimetics) as of the 2025 WADA Prohibited List. Any competitive athlete subject to WADA, USADA, or sport-specific anti-doping testing faces a significant sanction risk. The detection window in urine is not fully characterized for all testing methodologies, making risk estimation unreliable.

As the FDA stated in its 2017 advisory on SARMs and related compounds, investigational compounds sold as supplements carry contamination and mislabeling risks. Sourcing from compounding pharmacies operating under USP standards reduces but does not eliminate this risk.

Expected Timeline of Outcomes for Endurance Athletes

The Nass et al. And Chapman et al. Data, combined with practitioner observation, suggest the following approximate timeline for endurance athletes using 25 mg nightly:

• Weeks 1 to 2: Improved subjective sleep depth, morning recovery scores up, scale weight increases 1 to 3 kg (fluid).
• Weeks 3 to 6: Measurable IGF-1 rise (40 to 80% above baseline in RCT data); appetite increase stabilizes; water retention plateaus.
• Weeks 8 to 12: Athletes often report reduced DOMS after long runs or rides, faster return to training after high-intensity blocks, and subjective joint comfort improvement.
• Weeks 16 to 24: Body composition shifts become measurable: lean mass preservation or modest increase even in caloric maintenance; fat mass may decrease slightly in athletes maintaining training load.
• Beyond 24 weeks: No tachyphylaxis in the Nass et al. 24-month data; IGF-1 remained elevated at 40% above baseline throughout.